🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting in excess of 82 million instances annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Global Access

According to findings released by a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses an injection and a pill. The trial involved nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have voiced optimism. Having a one-pill regimen of this kind is hailed as a "critical tool" for public health efforts. This is viewed as vital to lessen the impact of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.